Table 3 Hazards ratio (HR) and 95% CI for developing cardiotoxicity
From: Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity
Univariable | Multivariable | |||
|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
GLS | 1.20 (1.05,1.38) | 0.01 | 1.17 (1.00,1.36) | 0.044 |
GLS[≥(-18%) vs <(-18%)] | 4.44 (1.83,10.8) | < 0.001 | 3.54 (1.34,9.35) | 0.011 |
Age | 1.04 (1.01,1.07) | 0.01 | ||
Male | 2.56 (1.13,5.8) | 0.02 | ||
BMI | 1.01 (.94,1.08) | 0.87 | ||
Systolic | 1.03 (1,1.05) | 0.02 | 1.03 (1.01,1.05) | 0.012 |
HR | 1.01 (.97,1.04) | 0.7 | ||
LVEF | 0.85 (.76,.94) | < 0.001 | ||
Caucasian | 1.67 (.71,3.94) | 0.24 | ||
Family Hx of heart disease | 1.99 (.68,5.86) | 0.21 | ||
Diabetes | 1.76 (.69,4.49) | 0.23 | ||
HTN | 3.55 (1.46,8.63) | 0.01 | ||
Hyperlipidemia | 1.51 (.64,3.56) | 0.35 | ||
CAD | 1.03 (.14,7.72) | 0.97 | ||
Hypothyroidism | 0.34 (.05,2.53) | 0.29 | ||
Smoking | 6.86 (2.9,16.21) | < 0.001 | 5.29 (2.09,13.39) | < 0.001 |
Breast cancer | 0.24 (.08,.69) | 0.01 | ||
Chemotherapy dose | 0.99 (.99,1) | 0.01 | 0.994 (0.989,0.999) | 0.018 |